Table 4 Unadjusted and Adjusted HRs for overall survival stratified by tumor stage and pretreatment NLR in cohort 1 (N = 378).

From: Pretreatment neutrophil-to-lymphocyte ratio and its dynamic changes are associated with the overall survival in advanced cancer patients undergoing palliative care

Stage + NLR

Unadjusted

Adjusted*

HR

95% CI

P

HR

95% CI

P

IV + HNLR (n = 270)

Reference

~

 

Reference

~

 

IV + LNLR (n = 85)

0.709

0.539~0.931

0.013

0.659

0.487~0.893

0.007

III + HNLR (n = 19)

0.212

0.104~0.430

<0.001

0.226

0.104~0.489

<0.001

III + LNLR (n = 4)#

—

—

 

—

—

 
  1. NLR: neutrophi-to-lymphocyte ratio; HR, hazard ratio; CI, confidence interval
  2. *Cox regression model controlling for Age; Gender; Primary tumor site; Palliative care; Family history; Smoke history; Nutrient status; Concomitant disease; Hospital stay; Albumin level.
  3. #No events in III + LNLR group.
Back to article page